遺伝子療法向け出発物質の世界市場：市場規模・シェア・動向分析 (製品別・開発段階別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

遺伝子療法向け出発物質市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の遺伝子療法向け出発物質の市場規模は2030年までに54億米ドルに達すると予測され、2025年から2030年までのCAGRは19.24%で成長すると予測されています。

この成長の原動力となっているのは、希少疾患や遺伝性疾患、がん、その他の複雑な病態を標的とする遺伝子治療のパイプラインの拡大をサポートするための高品質原料に対する需要の増加です。より多くの治療法が臨床試験を経て規制当局の承認を得るにつれて、スケーラブルでGMP準拠のプラスミド、ウイルスベクター、その他の主要インプットのニーズは高まり続けています。

さらに、技術進歩、研究開発投資の増加、規制の枠組みが市場をさらに加速させています。加えて、バイオテクノロジー企業と製造業者間の提携が生産能力を強化し、一貫したサプライチェーンを確保することで、遺伝子治療向け出発材料業界は予測期間を通じて力強く持続的な成長を遂げるものと位置づけられています。

COVID-19パンデミックは、迅速な治療開発とスケーラブルな製造の必要性を浮き彫りにし、遺伝子療法向け出発物質の需要をさらに加速させました。その結果、高度な生物生産インフラへの投資が促進され、遺伝子プラットフォームへの注目が高まり、プラスミドDNA、ウイルスベクター、ワクチンと遺伝子治療の両方の開発に使用されるその他の重要なコンポーネントの成長が促進されました。

さらに、遺伝子治療のパイプラインが拡大していることも、市場の成長に拍車をかけています。より多くの治療法が臨床試験に進み、規制当局の承認を受けるにつれて、プラスミドDNAやウイルスベクターのような高品質の出発物質に対する需要は増加の一途をたどっています。このため、製造能力、先端技術、戦略的パートナーシップへの投資が増加し、世界中の遺伝子治療開発者の進化するニーズに対応するための効率的なスケールアップと供給が可能となっています。

しかし、安全性、品質、コンプライアンスに関する厳しい規制要件は、遺伝子治療製品の開発と承認を遅らせる可能性があります。患者の安全を確保するために不可欠である一方で、こうした規制には複雑な文書化、広範な試験、長期化する審査スケジュールが含まれることが多いです。これは市場参入を遅らせ、運営コストを増加させ、規制に関する専門知識の乏しい中小企業にとっては障壁となります。業界が発展するにつれ、遺伝子療法向け出発物質市場の利害関係者にとって、これらの要件をうまく乗り切ることは依然として重要な課題となっています。

遺伝子療法向け出発物質市場レポートハイライト

• ウイルスベクターのセグメントは、遺伝子導入効率が高く、承認された遺伝子治療で広く使用されていることから、2024年には42.91%の最大売上シェアで市場をリードしました。しかし、プラスミドDNAセグメントは予測期間中20.13%のCAGRで最も速い成長が見込まれます。
• 開発段階に基づくと、治験段階の治療薬は2024年に最大の市場シェアを占め手織り、これは臨床試験を進める遺伝子治療候補の増加によるものです。一方、前臨床段階の治療薬は予測期間中に最も速いCAGRで示される見込みです。
• 用途別では、がん分野が2024年に最大の収益シェアを占め、予測期間中に最も速いCAGRで成長すると予測されています。これは、がん有病率の上昇、強力な臨床パイプライン、さまざまな腫瘍型を標的とする遺伝子治療の採用が増加していることに起因します。しかし、遺伝性疾患セグメントは予測期間中にCAGRで大きく成長すると予測されています。
• 最終用途に基づくと、遺伝子治療研究開発への投資の増加、自社製造能力、治療開発を加速するための戦略的パートナーシップなどが牽引し、バイオ医薬品・製薬企業セグメントが2024年に最大の市場収益シェアを占めました。一方、CRO・CMO分野は予測期間中に最も速いCAGRを記録すると予想されています。
• 北米は、強力な研究開発投資、高度な製造能力、業界リーダーの集中により、2024年の売上高シェアで市場を独占しました。アジア太平洋地域は予測期間中に最も速いCAGRで成長する見込みです。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 遺伝子療法向け出発物質市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 遺伝子療法向け出発物質市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 遺伝子療法向け出発物質市場：製品別の推定・動向分析

• 製品別のダッシュボード
• 世界の遺伝子療法向け出発物質市場：製品別の変動分析
• 世界の遺伝子療法向け出発物質市場：市場規模の予測と動向分析、製品別 (2018～2030年)
• ウイルスベクター
  • ウイルスベクター市場規模・予測・動向分析（2018～2030年）
  • アデノウイルス
  • レトロウイルス
  • アデノ随伴ウイルス（AAV）
  • レンチウイルス
  • その他
• プラスミドDNA
  • プラスミドDNA市場規模と予測および動向分析、2018年～2030年
• 細胞株
  • 細胞株市場規模と予測および動向分析、2018年～2030年
• その他
  • その他市場規模と予測および動向分析、2018～2030年

第5章 遺伝子療法向け出発物質市場：開発段階別の推定・動向分析

• 開発段階別のダッシュボード
• 世界の遺伝子療法向け出発物質市場：開発段階別の変動分析
• 世界の遺伝子療法向け出発物質市場：市場規模の予測と動向分析、開発段階別 (2018～2030年)
• 前臨床段階の治療薬
  • 前臨床段階の治療薬：市場規模の予測と動向分析（2018～2030年）
• 治験段階の治療薬
  • 治験段階の治療薬：市場規模の予測と動向分析（2018～2030年）
• 市販治療薬
  • 市販治療薬：市場規模の予測と動向分析（2018～2030年）

第6章 遺伝子療法向け出発物質市場：用途別の推定・動向分析

• 用途別のダッシュボード
• 世界の遺伝子療法向け出発物質市場：用途別の変動分析
• 世界の遺伝子療法向け出発物質市場：市場規模の予測と動向分析、用途別 (2018～2030年)
• 腫瘍
  • 腫瘍：市場規模の予測と動向分析（2018～2030年）
• 感染症
  • 感染症：市場規模の予測と動向分析（2018～2030年）
• 遺伝性疾患
• その他
  • その他：市場規模の予測と動向分析（2018～2030年）

第7章 遺伝子療法向け出発物質市場：最終用途別の推定・動向分析

• 最終用途別のダッシュボード
• 世界の遺伝子療法向け出発物質市場：最終用途別の変動分析
• 世界の遺伝子療法向け出発物質市場：市場規模の予測と動向分析、最終用途別 (2018～2030年)
• バイオ医薬品・製薬企業
  • バイオ医薬品・製薬企業：市場規模の予測と動向分析（2018～2030年）
• CRO・CMO
  • CRO・CMO：市場規模の予測と動向分析（2018～2030年）
• その他
  • その他：市場規模の予測と動向分析（2018～2030年）

第8章 遺伝子療法向け出発物質市場：地域別の推定・動向分析

• 市場シェア分析：地域別（2024年・2030年）
• 市場ダッシュボード：地域別
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参入企業
• 企業市況分析（2024年）
• 戦略マッピング
• 参入企業の概要
  • チャールズリバーラボラトリーズ
  • サーモフィッシャーサイエンティフィック株式会社
  • ジェンスクリプト
  • ロンザ
  • カタレント
  • ユーロフィンサイエンティフィック
  • ダナハー
  • メルクKGaA
  • 株式会社レブビティ
  • ザルトリウスAG

List of Tables

• Table 1 List of abbreviations
• Table 2 North America Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
• Table 3 North America Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 4 North America Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 5 North America Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 6 North America Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 7 US Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 8 US Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 9 US Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 10 US Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 11 Canada Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 12 Canada Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 13 Canada Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 14 Canada Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 15 Mexico Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 16 Mexico Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 17 Mexico Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 18 Mexico Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 19 Europe Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
• Table 20 Europe Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 21 Europe Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 22 Europe Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 23 Europe Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 24 UK Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 25 UK Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 26 UK Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 27 UK Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 28 Germany Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 29 Germany Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 30 Germany Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 31 Germany Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 32 Italy Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 33 Italy Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 34 Italy Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 35 Italy Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 36 France Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 37 France Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 38 France Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 39 France Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 40 Spain Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 41 Spain Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 42 Spain Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 43 Spain Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 44 Sweden Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 45 Sweden Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 46 Sweden Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 47 Sweden Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 48 Denmark Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 49 Denmark Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 50 Denmark Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 51 Denmark Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 52 Norway Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 53 Norway Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 54 Norway Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 55 Norway Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 61 China Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 62 China Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 63 China Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 64 China Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 65 Japan Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 66 Japan Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 67 Japan Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 68 Japan Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 69 India Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 70 India Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 71 India Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 72 India Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 73 South Korea Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 74 South Korea Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 75 South Korea Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 76 South Korea Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 77 Australia Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 78 Australia Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 79 Australia Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 80 Australia Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 81 Thailand Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 82 Thailand Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 83 Thailand Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 84 Thailand Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 85 Latin America Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
• Table 86 Latin America Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 87 Latin America Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 88 Latin America Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 89 Latin America Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 90 Brazil Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 91 Brazil Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 92 Brazil Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 93 Brazil Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 94 Argentina Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 95 Argentina Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 96 Argentina Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 97 Argentina Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 98 Middle East Africa Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
• Table 99 Middle East Africa Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 100 Middle East Africa Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 101 Middle East Africa Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 102 Middle East Africa Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 103 South Africa Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 104 South Africa Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 105 South Africa Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 106 South Africa Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 111 UAE Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 112 UAE Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 113 UAE Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 114 UAE Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
• Table 115 Kuwait Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
• Table 116 Kuwait Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
• Table 117 Kuwait Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
• Table 118 Kuwait Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Data Triangulation Techniques
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Market formulation & Validation
• Fig. 6 Gene Therapy Starting Materials Market: Market Outlook
• Fig. 7 Parent Market Outlook
• Fig. 8 Related/Ancillary Market Outlook
• Fig. 9 Gene Therapy Starting Materials Market Driver Impact
• Fig. 10 Gene Therapy Starting Materials Market Restraint Impact
• Fig. 11 Gene Therapy Starting Materials Market Strategic Initiatives Analysis
• Fig. 12 Gene Therapy Starting Materials Market: Product Movement Analysis
• Fig. 13 Gene Therapy Starting Materials Market: Product Outlook and Key Takeaways
• Fig. 14 Viral Vectors Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 15 Adenovirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 16 Retrovirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 17 Adeno-Associated Virus (AAV) Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 18 Lentivirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 19 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 20 Cell Lines Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 21 Plasmid DNA Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 22 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 23 Gene Therapy Starting Materials Market: Development Stage Movement Analysis
• Fig. 24 Gene Therapy Starting Materials Market: Development Stage Outlook and Key Takeaways
• Fig. 25 Pre-clinical Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Clinical Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Marketed Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Gene Therapy Starting Materials Market: Application Movement Analysis
• Fig. 29 Gene Therapy Starting Materials Market: Application Outlook and Key Takeaways
• Fig. 30 Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Infectious Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Genetic Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Other Disease Diagnostic Applications Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Gene Therapy Starting Materials Market: End-Use Movement Analysis
• Fig. 37 Gene Therapy Starting Materials Market: End-Use Outlook and Key Takeaways
• Fig. 38 Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 39 CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Global Gene Therapy Starting Materials Market: Regional Movement Analysis
• Fig. 42 Global Gene Therapy Starting Materials Market: Regional Outlook and Key Takeaways
• Fig. 43 North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 44 US Country Dynamics
• Fig. 45 US Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Canada Country Dynamics
• Fig. 47 Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Mexico Country Dynamics
• Fig. 49 Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 51 UK Country Dynamics
• Fig. 52 UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Germany Country Dynamics
• Fig. 54 Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 55 France Country Dynamics
• Fig. 56 France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Italy Country Dynamics
• Fig. 58 Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Spain Country Dynamics
• Fig. 60 Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Denmark Country Dynamics
• Fig. 62 Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Sweden Country Dynamics
• Fig. 64 Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Norway Country Dynamics
• Fig. 66 Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 68 China Country Dynamics
• Fig. 69 China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Japan Country Dynamics
• Fig. 71 Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 72 India Country Dynamics
• Fig. 73 India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Thailand Country Dynamics
• Fig. 75 Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 76 South Korea Country Dynamics
• Fig. 77 South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Australia Country Dynamics
• Fig. 79 Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Brazil Country Dynamics
• Fig. 82 Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Argentina Country Dynamics
• Fig. 84 Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Middle East and Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 86 South Africa Country Dynamics
• Fig. 87 South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Saudi Arabia Country Dynamics
• Fig. 89 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 90 UAE Country Dynamics
• Fig. 91 UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Kuwait Country Dynamics
• Fig. 93 Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Market Position of Key Market Players

Gene Therapy Starting Materials Market Growth & Trends:

The global gene therapy starting materials market size is anticipated to reach USD 5.40 billion by 2030 and is projected to grow at a CAGR of 19.24% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for high-quality raw materials to support the expanding pipeline of gene therapies targeting rare and genetic disorders, cancer, and other complex conditions. As more therapies advance through clinical trials and gain regulatory approvals, the need for scalable, GMP-compliant plasmids, viral vectors, and other key inputs continues to rise.

Furthermore, technological advancements, growing R&D investments, and supportive regulatory frameworks are further accelerating the market. In addition, partnerships between biotech firms and manufacturers are enhancing production capabilities and ensuring a consistent supply chain, positioning the gene therapy starting materials industry for strong and sustained growth through the forecast period.

The COVID-19 pandemic further accelerated the demand for gene therapy starting materials by highlighting the need for rapid therapeutic development and scalable manufacturing. It spurred investments in advanced bioproduction infrastructure and increased focus on genetic platforms, driving growth in plasmid DNA, viral vectors, and other critical components used in both vaccine and gene therapy development.

In addition, the expanding pipeline of gene therapies has further fueled market growth. As more therapies advance into clinical trials and receive regulatory approvals, the demand for high-quality starting materials such as plasmid DNA and viral vectors continues to rise. This has prompted increased investments in manufacturing capacity, advanced technologies, and strategic partnerships, enabling efficient scale-up and supply to meet the evolving needs of gene therapy developers worldwide.

However, strict regulatory requirements for safety, quality, and compliance can delay the development and approval of gene therapy products. While essential for ensuring patient safety, these regulations often involve complex documentation, extensive testing, and prolonged review timelines. This can slow market entry, increase operational costs, and create barriers for smaller companies with limited regulatory expertise. As the industry evolves, navigating these requirements remains a critical challenge for stakeholders in the gene therapy starting materials market.

Gene Therapy Starting Materials Market Report Highlights:

• The viral vectors segment led the market with the largest revenue share of 42.91% in 2024, owing to their high efficiency in gene delivery and widespread use in approved gene therapies. However, the plasmid DNA segment is expected to grow at the fastest CAGR of 20.13% over the forecast period.
• Based on development stage, the clinical therapeutics segment accounted for the largest market share in 2024, driven by the growing number of gene therapy candidates advancing through clinical trials. On the other hand, the pre-clinical therapeutics segment is expected to witness at the fastest CAGR over the forecast period.
• Based on application, the oncology segment accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, attributed to the rising prevalence of cancer, strong clinical pipeline, and increasing adoption of gene therapies targeting various tumor types. However, the genetic disease segment is projected to grow at a significant CAGR over the forecast period.
• Based on end use, the biopharmaceutical and pharmaceutical companies segment accounted for the largest market revenue share in 2024, driven by increased investment in gene therapy R&D, in-house manufacturing capabilities, and strategic partnerships to accelerate therapy development. On the other hand, the CROs & CMOs segment is expected to register at the fastest CAGR during the projected period.
• North America dominated the market with the largest revenue share in 2024 due to strong R&D investment, advanced manufacturing capabilities, and a high concentration of industry leaders. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Development Stage
  • 1.2.3. Application
  • 1.2.4. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Therapy Starting Materials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Genetic and Rare Diseases
    • 3.2.1.2. Expanding Pipeline of Gene Therapies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Strict Regulatory Requirements
• 3.3. Gene Therapy Starting Materials Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Gene Therapy Starting Materials Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Gene Therapy Starting Materials Market Product Movement Analysis
• 4.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Viral Vectors
  • 4.4.1. Viral Vectors Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.4.2. Adenovirus
    • 4.4.2.1. Adenovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Retrovirus
    • 4.4.3.1. Retrovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Adeno-Associated Virus (AAV)
    • 4.4.4.1. Adeno-Associated Virus (AAV) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Lentivirus
    • 4.4.5.1. Lentivirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
• 4.5. Plasmid DNA
  • 4.5.1. Plasmid DNA Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 4.6. Cell Lines
  • 4.6.1. Cell Lines Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 5. Gene Therapy Starting Materials Market: Development Stage Estimates & Trend Analysis

• 5.1. Development Stage Segment Dashboard
• 5.2. Global Gene Therapy Starting Materials Market Development Stage Movement Analysis
• 5.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Pre-clinical Therapeutics
  • 5.4.1. Pre-clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.5. Clinical Therapeutics
  • 5.5.1. Clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.6. Marketed Therapeutics
  • 5.6.1. Marketed Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 6. Gene Therapy Starting Materials Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Gene Therapy Starting Materials Market Application Movement Analysis
• 6.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
• 6.5. Infectious Disease
  • 6.5.1. Infectious Disease Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
• 6.6. Genetic Disease
  • 6.6.1. Genetic Disease Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)

Chapter 7. Gene Therapy Starting Materials Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Gene Therapy Starting Materials Market End Use Movement Analysis
• 7.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Biopharmaceutical & Pharmaceutical Companies
  • 7.4.1. Biopharmaceutical & Pharmaceutical Companies Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 7.5. CROs & CMOs
  • 7.5.1. CROs & CMOs Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 7.6. Other
  • 7.6.1. Other Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 8. Gene Therapy Starting Materials Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Company Market Position Analysis, 2024
• 9.3. Strategy Mapping
• 9.4. Participants Overview
  • 9.4.1. Charles River Laboratories
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. GenScript
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Lonza
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Catalent
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Eurofins Scientific
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Danaher
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Merck KGaA
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Revvity, Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Sartorius AG
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives